TONADO 1&2 were 52-week, double-blind, parallel-group studies in which patients with moderate to very severe COPD were randomized to receive olodaterol 5mcg, tiotropium 2.5mcg, tiotropium 5mcg, tiotropium/olodaterol 2.5/5mcg or tiotropium/olodaterol 5/5mcg, all delivered via the Respimat inhaler.
After 24 weeks of treatment, tiotropium/olodaterol Respimat 5/5mcg improved lung function, as measured by trough FEV1, compared to tiotropium Respimat 5mcg in patients who were untreated and previously treated with maintenance bronchodilator therapy (mean increase 76mL vs. 48mL, respectively). Tiotropium/olodaterol Respimat 5/5mcg provided statistically significant improvements in lung function, as measured by trough FEV1 and FEV1AUC0-3, compared to tiotropium Respimat 5mcg and olodaterol Respimat 5mcg alone in patients across all COPD stages. Tiotropium/olodaterol Respimat 5/5mcg demonstrated statistically significant improvement of lung function over tiotropium Respimat 5mcg and olodaterol Respimat 5mcg irrespective of whether patients were taking inhaled corticosteroids (ICS) at the start of the trials.
For more information call (800) 542-6257 or visit Boehringer-Ingelheim.com.